Senzer N - Search Results

1

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis.

Santoro A, Simonelli M, Rodriguez-Lope C, Zucali P, Camacho LH, Granito A, Senzer N, Rimassa L, Abbadessa G, Schwartz B, Lamar M, Savage RE, Bruix J. Santoro A, et al. Among authors: senzer n. Br J Cancer. 2013 Jan 15;108(1):21-4. doi: 10.1038/bjc.2012.556. Epub 2013 Jan 3. Br J Cancer. 2013. PMID: 23287988 Free PMC article. Clinical Trial.

2

A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.

Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE, Waghorne C, Abbadessa G, Schwartz B, Dreicer R. Rosen LS, et al. Among authors: senzer n. Clin Cancer Res. 2011 Dec 15;17(24):7754-64. doi: 10.1158/1078-0432.CCR-11-1002. Epub 2011 Oct 5. Clin Cancer Res. 2011. PMID: 21976535 Clinical Trial.

3

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.

Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD. Wagner AJ, et al. Among authors: senzer n. Cancer. 2012 Dec 1;118(23):5894-902. doi: 10.1002/cncr.27582. Epub 2012 May 17. Cancer. 2012. PMID: 22605650 Free article. Clinical Trial.

4

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.

Bowles DW, Ma WW, Senzer N, Brahmer JR, Adjei AA, Davies M, Lazar AJ, Vo A, Peterson S, Walker L, Hausman D, Rudin CM, Jimeno A. Bowles DW, et al. Among authors: senzer n. Br J Cancer. 2013 Sep 3;109(5):1085-92. doi: 10.1038/bjc.2013.474. Epub 2013 Aug 13. Br J Cancer. 2013. PMID: 23942080 Free PMC article. Clinical Trial.

5

Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.

Goyal L, Supko JG, Berlin J, Blaszkowsky LS, Carpenter A, Heuman DM, Hilderbrand SL, Stuart KE, Cotler S, Senzer NN, Chan E, Berg CL, Clark JW, Hezel AF, Ryan DP, Zhu AX. Goyal L, et al. Among authors: senzer nn. Cancer Chemother Pharmacol. 2013 Dec;72(6):1305-14. doi: 10.1007/s00280-013-2293-8. Cancer Chemother Pharmacol. 2013. PMID: 24121453 Clinical Trial.

6

Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.

Mahalingam D, Nemunaitis JJ, Malik L, Sarantopoulos J, Weitman S, Sankhala K, Hart J, Kousba A, Gallegos NS, Anderson G, Charles J, Rogers JM, Senzer NN, Mita AC. Mahalingam D, et al. Among authors: senzer nn. Cancer Chemother Pharmacol. 2014 Dec;74(6):1241-50. doi: 10.1007/s00280-014-2602-x. Epub 2014 Oct 11. Cancer Chemother Pharmacol. 2014. PMID: 25304209 Clinical Trial.

7

A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer.

Segal NH, Gada P, Senzer N, Gargano MA, Patchen ML, Saltz LB. Segal NH, et al. Among authors: senzer n. Clin Colorectal Cancer. 2016 Sep;15(3):222-7. doi: 10.1016/j.clcc.2016.02.013. Epub 2016 Feb 13. Clin Colorectal Cancer. 2016. PMID: 26975418 Free PMC article. Clinical Trial.

8

A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.

Bowles DW, Senzer N, Hausman D, Peterson S, Vo A, Walker L, Cohen RB, Jimeno A. Bowles DW, et al. Among authors: senzer n. Invest New Drugs. 2014 Dec;32(6):1197-203. doi: 10.1007/s10637-014-0124-3. Epub 2014 Jun 12. Invest New Drugs. 2014. PMID: 24916771 Clinical Trial.

9

Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.

Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, Pappen B, Maples PB, Shawler D, Fakhrai H. Nemunaitis J, et al. Among authors: senzer n. Cancer Gene Ther. 2009 Aug;16(8):620-4. doi: 10.1038/cgt.2009.15. Epub 2009 Mar 13. Cancer Gene Ther. 2009. PMID: 19287371 Clinical Trial.

10

Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer.

Nemunaitis J, Eiseman I, Cunningham C, Senzer N, Williams A, Lenehan PF, Olson SC, Bycott P, Schlicht M, Zentgraff R, Shin DM, Zinner RG. Nemunaitis J, et al. Among authors: senzer n. Clin Cancer Res. 2005 May 15;11(10):3846-53. doi: 10.1158/1078-0432.CCR-04-1950. Clin Cancer Res. 2005. PMID: 15897585 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

120 results

Search Page

Filters